Monopar Therapeutics Files 8-K for Regulation FD Disclosure

TL;DR

Monopar filed an 8-K for a Reg FD disclosure, no new material info disclosed.

AI Summary

Monopar Therapeutics Inc. filed an 8-K on March 7, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material events beyond the disclosure itself.

Why It Matters

This filing indicates Monopar Therapeutics is making a public disclosure under Regulation FD, ensuring all investors receive the same material information simultaneously.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain information that inherently increases or decreases risk.

Key Players & Entities

• Monopar Therapeutics Inc. (company) — Registrant
• March 7, 2024 (date) — Filing date
• Regulation FD (regulation) — Disclosure type

FAQ

From the Filing

0001437749-24-006900.txt : 20240307 0001437749-24-006900.hdr.sgml : 20240307 20240307083014 ACCESSION NUMBER: 0001437749-24-006900 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240307 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 24728237 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20240305_8k.htm FORM 8-K mnpr20240305_8k.htm false 0001645469 0001645469 2024-03-07 2024-03-07     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):   March 7, 2024   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒           Item 7.01   Regulation FD Disclosure.     On March 7, 2024, Monopar Therapeutics Inc. posted their radiopharma presentation which is available under the Investor section of their website www.monopartx.com.           SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     Monopar Therapeutics Inc.           Date: March 7, 2024 By: /s/ Kim R. Tsuchimoto     Name: Kim R. Tsuchimoto     Title: Chief Financial Officer and